AUPH - Aurinia Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Aurinia Pharmaceuticals Inc.

4464 Markham Street
Suite 1203
Victoria, BC V8Z 7X8

Full Time Employees39

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael R. MartinCo-Founder & COO350.57kN/AN/A
Mr. Dennis Bourgeault CPA, C.A.CFO & Sec.329.19kN/AN/A
Dr. Robert B. Huizinga M.Sc., Ph.D., RN NNC, MSc(Epi), CNeph(C)Exec. VP of Corp. Devel.436.26kN/AN/A
Dr. Richard M. GlickmanAdvisor887.25kN/A1958
Dr. Neil Solomons M.D.Chief Medical Officer471.21kN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

Corporate Governance

Aurinia Pharmaceuticals Inc.’s ISS Governance QualityScore as of June 25, 2019 is 3. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.